Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Sees Significant Growth in Short Interest

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) was the target of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 1,720,000 shares, a growth of 34.4% from the January 31st total of 1,280,000 shares. Currently, 10.1% of the shares of the stock are short sold. Based on an average daily volume of 192,900 shares, the days-to-cover ratio is presently 8.9 days.

Telomir Pharmaceuticals Trading Up 2.0 %

Shares of NASDAQ TELO opened at $4.13 on Thursday. Telomir Pharmaceuticals has a twelve month low of $3.11 and a twelve month high of $9.39. The company has a market capitalization of $122.92 million and a price-to-earnings ratio of -7.12. The firm has a 50-day moving average of $4.42 and a two-hundred day moving average of $4.86.

Telomir Pharmaceuticals (NASDAQ:TELO) last issued its quarterly earnings results on Tuesday, February 4th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). As a group, research analysts predict that Telomir Pharmaceuticals will post -0.4 earnings per share for the current year.

Institutional Investors Weigh In On Telomir Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of TELO. Gotham Asset Management LLC acquired a new stake in Telomir Pharmaceuticals in the 4th quarter valued at about $28,000. Rhumbline Advisers lifted its holdings in Telomir Pharmaceuticals by 105.9% in the 4th quarter. Rhumbline Advisers now owns 8,600 shares of the company’s stock valued at $35,000 after acquiring an additional 4,424 shares during the last quarter. Corebridge Financial Inc. lifted its holdings in Telomir Pharmaceuticals by 273.8% in the 4th quarter. Corebridge Financial Inc. now owns 9,613 shares of the company’s stock valued at $40,000 after acquiring an additional 7,041 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Telomir Pharmaceuticals by 458.3% during the 4th quarter. Wells Fargo & Company MN now owns 10,044 shares of the company’s stock worth $41,000 after buying an additional 8,245 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Telomir Pharmaceuticals by 279.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,699 shares of the company’s stock worth $44,000 after buying an additional 7,879 shares during the period.

Analyst Ratings Changes

TELO has been the subject of several research analyst reports. Rodman & Renshaw initiated coverage on shares of Telomir Pharmaceuticals in a report on Friday, February 21st. They issued a “buy” rating and a $15.00 price objective for the company. RODMAN&RENSHAW raised shares of Telomir Pharmaceuticals to a “strong-buy” rating in a report on Thursday, February 20th.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.